

Overview Pharmacotherapy (2024)

Substance	Approved in CH	Listed on SL	UFC no rate	Pregnancy	Side effects	Disadvantage
Ketoconazol	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Up to ~65%	<input checked="" type="checkbox"/>	Hepatotoxicity GIT symptoms Androgen deficit	Monitoring (ALAT) Interaction (CYP450) Disponibility
Metyrapon (Metopiron®)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Up to ~65%	<input checked="" type="checkbox"/>	GIT Symptoms Androgen excess Mineralocorticoid excess	3 to 4 intakes a day
Osilodrostat (Isturisa®)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Up to ~80%	<input checked="" type="checkbox"/>	GIT Symptoms Arthralgias / Myalgias Hirsutism / Edema Adrenal Insufficiency	Price (dose dependent; ~3000 - >6000 CHF/Mt) Long-Term Data?
Mitotane (Lysodren®)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> (only ACC)	Up to ~70%	<input checked="" type="checkbox"/>	GIT Symptoms, Neurotoxicity Hypothyroidism Hypogonadism Gynaecomastia	Monitoring (Serum levels) Usually not very well tolerated
Pasireotide (Signifor®)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Only M. Cushing	Up to ~25% Combi?	<input checked="" type="checkbox"/>	Hyperglycemia / Diabetes GIT-Symptoms (Gallstones)	Effect esp. in moderate hypercorticism No injection device Price (~. 5000 CHF/Mt.)
Cabergolin (Cabaser®/ Dostinex®)	<input checked="" type="checkbox"/> Prolactinomas	<input checked="" type="checkbox"/>	Up to 30 % Combi?	<input checked="" type="checkbox"/>	Nausea Dizziness	Long Term Efficacy? Option in moderate hypercorticism

Table 1 Medical therapy for Cushing's disease

Classification	Drug name	Dose	Possible adverse events; Close monitoring is necessary for all drugs
Steroidogenesis inhibitors	Ketoconazole	Oral 200–1200 mg/day 2–3 times a day	Hepatitis, gastrointestinal disturbances, gynecomastia, skin rash, adrenal insufficiency.
	Fluconazole	Oral 100–200 mg/day 2 times a day	AEs similar to ketoconazole, not well studied
	Metyrapone	Oral 0.5–6 g/day 4 times a day	Hirsutism, acne, hypertension, hypokalemia, edema, gastritis, nausea, adrenal insufficiency.
	Etomidate	IV bolus of 0.03 mg/kg followed by 0.02–0.08 mg/kg/h	Somnolence, myodonus, nausea, vomiting, dystonic reactions, adrenal insufficiency.
	Mitotane	Oral 2–5 g/day 3 times a day	Gastrointestinal disturbances, hepatitis, neurologic manifestations, gynecomastia, neutropenia, lipid disorders, adrenal insufficiency, teratogenic
	Osilodrostat	Oral 10–60 mg/day; phase III clinical trial: NCT 02180217	Nausea, asthenia, diarrhea, adrenal insufficiency. Testosterone increase in women.
	Levoketoconazole	Oral 400 mg /day; phase III clinical trial: NCT 01838551	N/A.
Dopamine D2R agonists	Cabergoline	Oral 0.5–7 mg/week	Headache, nausea, dizziness, nasal congestion, hypotension, depression
SRLs	Pasireotide ^a	SC 300–1800 µg/day 2 times a day	Hyperglycemia, diabetes, diarrhea, nausea, abdominal pain, cholelithiasis, QT prolongation
	Pasireotide LAR	IM 30–60 mg/month; phase III clinical trial	
GR antagonist	Mifepristone ^a	Oral 300–1200 mg/day Once daily	Nausea, fatigue, headache, hypokalemia, arthralgia, vomiting, peripheral edema, hypertension, dizziness, adrenal insufficiency, PAECs, endometrial thickening, vaginal bleeding; termination of pregnancy.
CDK2/Cyclin E inhibitor	R-Roscovitine	Oral Phase II clinical trial; clinicaltrials.gov identifier: NCT02160730	
Nuclear receptor ligand	Retinoic acid	Oral Phase II clinical trial; clinicaltrialsregister.eu number: 2008-006379-65	

D2R dopamine D2 receptor, SRL somatostatin receptor ligand, SC subcutaneous, IM intramuscular, LAR long-acting repeatable, PAECs- progesterone-receptor modulator-associated endometrial changes

^aFDA approved